Antiretroviral Nucleoside Analogues Suppress Antibody Synthesis in Human B-Lymphocytes

Palella F.J. Jr. , Delaney K.M. , Moorman A.C. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853–860.

Jordano Q. , Falco V. , Almirante B. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38: 1623–1628.

Heffernan R.T. , Barrett N.L. , Gallagher K.M. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005; 191: 2038–2045.

Walker U.A. , Setzer B. , Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16: 2165–2173.

Venhoff N. , Setzer B. , Melkaoui K. , Walker U.A. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther 2007; 12: 1075–1085.

Setzer B. , Schlesier M. , Thomas A.K. , Walker U.A. Mitochondrial toxicity of nucleoside analogues in primary human lymphocytes. Antivir Ther 2005; 10: 327–334.

Setzer B. , Schlesier M. , Walker U.A. Effects of of didanosine-related depletion of mtDNA in human T lymphocytes. J Infect Dis 2005; 191: 848–855.

Löffler M. , Jöckel J. , Schuster G. , Becker C. Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol Cell Biochem 1997; 174: 125–129.

Lewis W. , Day B.J. , Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003; 2: 812–822.

Walker U.A. , Venhoff N. Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity. Antivir Ther 2005; 10 Suppl 2: M117–M123.

Song S. , Pursell Z.F. , Copeland W.C. , Longley M.J. , Kunkel T.A. , Mathews C.K. DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity. Proc Natl Acad Sci U S A 2005; 102: 4990–4995.

Herrmann M.L. , Schleyerbach R. , Kirschbaum B.J. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000; 47: 273–289.

Cao W. , Sikorski E.E. , Fuchs B.A. , Stern M.L. , Luster M.I. , Munson A.E. The B lymphocyte is the immune cell target for 2′,3′-dideoxyadenosine. Toxicol Appl Pharmacol 1990; 105: 492–502.

Horster S. , Laubender R.P. , Lehmeyer L. Influence of antiretroviral therapy on immunogenicity of simultaneous vaccinations against influenza, pneumococcal disease and hepatitis A and B in human immunodeficiency virus positive individuals. J Infect 2010; 61: 484–491.

Rodriguez-Barradas M.C. , Alexandraki I. , Nazir T. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003; 37: 438–447.

Côté H.C. , Brumme Z.L. , Craib K.J. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346: 811–820.

Poirier M.C. , Divi R.L. , Al Harthi L. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003; 33: 175–183.

Miura T. , Goto M. , Hosoya N. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J Med Virol 2003; 70: 497–505.

Maagaard A. , Holberg-Petersen M. , Lovgarden G. , Holm M. , Pettersen F.O. , Kvale D. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment. J Infect Dis 2008; 198: 1474–1481.

Cossarizza A. Tests for mitochondrial function and DNA: potentials and pitfalls. Curr Opin Infect Dis 2003; 16: 5–10.

Walker U.A. , Bäuerle J. , Laguno M. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39: 311–317.

Walker U.A. , Bickel M. , Lütke Volksbeck S.I. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002; 29: 117–121.

Silva H.T. , Cao W. , Shorthouse R. , Morris R.E. Mechanism of action of leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation. Transplant Proc 1996; 28: 3082–3084.

Walker U.A. , Auclair M. , Lebrecht D. , Kornprobst M. , Capeau J. , Caron M. Uridine abrogates the adverse effects of stavudine and zalcitabine on adipose cell functions. Antivir Ther 2004; 9 Suppl 2: L10–L11.

Lebrecht D. , Vargas Infante Y.A. , Setzer B. , Kirschner J. , Walker U.A. Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. Hepatology 2007; 45: 72–79.

Lebrecht D. , Deveaud C. , Beauvoit B. , Bonnet J. , Kirschner J. , Walker U.A. Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemia in mice. Arthritis Rheum 2008; 58: 318–326.

Venhoff N. , Lebrecht D. , Deveaud C. Oral uridine supplementation antagonizes the peripheral neuropathy and encephalopathy induced by antiretroviral nucleoside analogues. AIDS 2010; 24: 345–352.

Setzer B. , Lebrecht D. , Walker U.A. Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine. Am J Pathol 2008; 172: 681–690.

Walker U.A. , Venhoff N. , Koch E. , Olschweski M. , Schneider J. , Setzer B. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 2003; 8: 463–470.

Walker U.A. , Auclair M. , Lebrecht D. , Kornprobst M. , Capeau J. , Caron M. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 2006; 11: 25–34.

Papp E. , Gadawski I. , Cote H.C. Longitudinal effects of thymidine analogues on mtDNA, mtRNA and multidrug resistance (MDR-1) induction in cultured cells. J Antimicrob Chemother 2008; 61: 1048–1052.

Purcet S. , Minuesa G. , Molina-Arcas M. 3′-Azido-2′,3′-dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes. Antivir Ther 2006; 11: 803–811.

Minuesa G. , Purcet S. , Erkizia I. Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells. J Pharmacol Exp Ther 2008; 324: 558–567.

Kakuda T.N. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685–708.

Negredo E. , Moltó J. , Burger D. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004; 18: 459–463.

Mond J.J. , Vos Q. , Lees A. , Snapper C.M. T cell independent antigens. Curr Opin Immunol 1995; 7: 349–354.

Abzug M.J. , Pelton S.I. , Song L.Y. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25: 920–929.

Setzer B. , Lebrecht D. , Walker U.A. Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine. Am J Pathol 2008; 172: 681–690.

Soler C. , Felipe A. , Mata J.F. , Casado F.J. , Celada A. , Pastor-Anglada M. Regulation of nucleoside transport by lipopolysaccharide, phorbol esters, and tumor necrosis factor-alpha in human B-lymphocytes. J Biol Chem 1998; 273: 26939–26945.

Fairbanks L.D. , Bofill M. , Ruckemann K. , Simmonds H.A. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 1995; 270: 29682–29689.

Toy G. , Austin W.R. , Liao H.I. Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci U S A 2010; 107: 5551–5556.

Thomson T.A. , Spinella-Jaegle S. , Francesconi E. In vitro and in vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine. Scand J Immunol 2002; 56: 35–42.